Discovery and preclinical validation of drug indications using compendia of public gene expression data.

Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A (2013) 16.74

Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol Ther (2013) 2.64

Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol (2012) 2.63

Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48

A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov (2013) 2.46

Comparison and validation of genomic predictors for anticancer drug sensitivity. J Am Med Inform Assoc (2013) 1.73

Computational solutions for omics data. Nat Rev Genet (2013) 1.58

Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov (2012) 1.42

Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. MBio (2013) 1.41

Transcriptional data: a new gateway to drug repositioning? Drug Discov Today (2012) 1.40

Molecular mechanisms underlying variations in lung function: a systems genetics analysis. Lancet Respir Med (2015) 1.40

A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med (2012) 1.38

LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res (2014) 1.34

Predicting new indications for approved drugs using a proteochemometric method. J Med Chem (2012) 1.29

Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc (2014) 1.25

Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today (2013) 1.24

Characterization of drug-induced transcriptional modules: towards drug repositioning and functional understanding. Mol Syst Biol (2013) 1.22

Managing drug resistance in cancer: lessons from HIV therapy. Nat Rev Cancer (2012) 1.19

InSilico DB genomic datasets hub: an efficient starting point for analyzing genome-wide studies in GenePattern, Integrative Genomics Viewer, and R/Bioconductor. Genome Biol (2012) 1.18

Automatic construction of a large-scale and accurate drug-side-effect association knowledge base from biomedical literature. J Biomed Inform (2014) 1.18

Complex-disease networks of trait-associated single-nucleotide polymorphisms (SNPs) unveiled by information theory. J Am Med Inform Assoc (2012) 1.17

A generalizable pre-clinical research approach for orphan disease therapy. Orphanet J Rare Dis (2012) 1.16

Unifying immunology with informatics and multiscale biology. Nat Immunol (2014) 1.15

Making sense out of massive data by going beyond differential expression. Proc Natl Acad Sci U S A (2012) 1.14

The emerging paradigm of network medicine in the study of human disease. Circ Res (2012) 1.12

A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. Cancer Res (2011) 1.09

The emergence of genome-based drug repositioning. Sci Transl Med (2011) 1.07

Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer. PLoS Comput Biol (2012) 1.06

Towards building a disease-phenotype knowledge base: extracting disease-manifestation relationship from literature. Bioinformatics (2013) 1.06

DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information. Cell Death Dis (2014) 1.05

Pathway-based drug repositioning using causal inference. BMC Bioinformatics (2013) 1.04

DvD: An R/Cytoscape pipeline for drug repurposing using public repositories of gene expression data. Bioinformatics (2012) 1.04

Collaborative biomedicine in the age of big data: the case of cancer. J Med Internet Res (2014) 1.04

Prediction of drug-target interactions for drug repositioning only based on genomic expression similarity. PLoS Comput Biol (2013) 1.02

Modules, networks and systems medicine for understanding disease and aiding diagnosis. Genome Med (2014) 1.02

Towards the understanding of microRNA and environmental factor interactions and their relationships to human diseases. Sci Rep (2012) 1.01

Network biology methods integrating biological data for translational science. Brief Bioinform (2012) 0.99

Drug-target interaction prediction through domain-tuned network-based inference. Bioinformatics (2013) 0.99

Replication Study: Discovery and preclinical validation of drug indications using compendia of public gene expression data. Elife (2017) 0.98

Predicting drug-target interactions using probabilistic matrix factorization. J Chem Inf Model (2013) 0.98

Automated detection of off-label drug use. PLoS One (2014) 0.96

Predicting drug-target interactions using restricted Boltzmann machines. Bioinformatics (2013) 0.95

CANDO and the infinite drug discovery frontier. Drug Discov Today (2014) 0.94

Translating Mendelian and complex inheritance of Alzheimer's disease genes for predicting unique personal genome variants. J Am Med Inform Assoc (2012) 0.93

DMAP: a connectivity map database to enable identification of novel drug repositioning candidates. BMC Bioinformatics (2015) 0.92

Registered report: Discovery and preclinical validation of drug indications using compendia of public gene expression data. Elife (2015) 0.92

Translational bioinformatics embraces big data. Yearb Med Inform (2012) 0.91

Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen. PLoS One (2012) 0.91

Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity. Sci Rep (2013) 0.90

Systems biology approaches for advancing the discovery of effective drug combinations. J Cheminform (2015) 0.90

Signatures for drug repositioning. Nat Rev Genet (2011) 0.90

Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research. BMC Med Genomics (2015) 0.90

Towards drug repositioning: a unified computational framework for integrating multiple aspects of drug similarity and disease similarity. AMIA Annu Symp Proc (2014) 0.89

Compensating for literature annotation bias when predicting novel drug-disease relationships through Medical Subject Heading Over-representation Profile (MeSHOP) similarity. BMC Med Genomics (2013) 0.89

Novel drug-regulated transcriptional networks in brain reveal pharmacological properties of psychotropic drugs. BMC Genomics (2013) 0.89

Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease. Pharmaceuticals (Basel) (2013) 0.88

DrugMap Central: an on-line query and visualization tool to facilitate drug repositioning studies. Bioinformatics (2013) 0.88

Functional Module Connectivity Map (FMCM): a framework for searching repurposed drug compounds for systems treatment of cancer and an application to colorectal adenocarcinoma. PLoS One (2014) 0.88

Understanding resistance to combination chemotherapy. Drug Resist Updat (2012) 0.88

Network-based in silico drug efficacy screening. Nat Commun (2016) 0.87

Quantitative imaging biomarker ontology (QIBO) for knowledge representation of biomedical imaging biomarkers. J Digit Imaging (2013) 0.86

Drug repurposing: a better approach for infectious disease drug discovery? Curr Opin Immunol (2013) 0.86

In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med (2016) 0.85

Pharmacogenomic and clinical data link non-pharmacokinetic metabolic dysregulation to drug side effect pathogenesis. Nat Commun (2015) 0.85

Network medicine in disease analysis and therapeutics. Clin Pharmacol Ther (2013) 0.85

Bioinformatic analysis of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels identify potential therapeutic targets. PLoS One (2012) 0.85

Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature. J Mark Access Health Policy (2013) 0.85

Systematic evaluation of connectivity map for disease indications. Genome Med (2014) 0.85

Mapping the effects of drugs on the immune system. Nat Biotechnol (2015) 0.84

Combining Human Disease Genetics and Mouse Model Phenotypes towards Drug Repositioning for Parkinson's disease. AMIA Annu Symp Proc (2015) 0.84

Recent Advances and Emerging Applications in Text and Data Mining for Biomedical Discovery. Brief Bioinform (2015) 0.84

Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct breast cancer metastases. Cancer Res (2013) 0.84

Drug-repurposing identified the combination of Trolox C and Cytisine for the treatment of type 2 diabetes. J Transl Med (2014) 0.84

Prediction of novel drug indications using network driven biological data prioritization and integration. J Cheminform (2014) 0.84

C²Maps: a network pharmacology database with comprehensive disease-gene-drug connectivity relationships. BMC Genomics (2012) 0.84

Computational drug repositioning through heterogeneous network clustering. BMC Syst Biol (2013) 0.84

Leveraging big data to transform target selection and drug discovery. Clin Pharmacol Ther (2016) 0.84

Adapting bioinformatics curricula for big data. Brief Bioinform (2015) 0.84

Relating Chemical Structure to Cellular Response: An Integrative Analysis of Gene Expression, Bioactivity, and Structural Data Across 11,000 Compounds. CPT Pharmacometrics Syst Pharmacol (2015) 0.83

PhenoPredict: A disease phenome-wide drug repositioning approach towards schizophrenia drug discovery. J Biomed Inform (2015) 0.83

Gene expression signature-based approach identifies a pro-resolving mechanism of action for histone deacetylase inhibitors. Cell Death Differ (2012) 0.83

Comparative gene expression profiling of benign and malignant lesions reveals candidate therapeutic compounds for leiomyosarcoma. Sarcoma (2012) 0.83

Network based elucidation of drug response: from modulators to targets. BMC Syst Biol (2013) 0.83

Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. Front Pharmacol (2014) 0.83

Surveying Recent Themes in Translational Bioinformatics: Big Data in EHRs, Omics for Drugs, and Personal Genomics. Yearb Med Inform (2014) 0.83

Assessing Concordance of Drug-Induced Transcriptional Response in Rodent Liver and Cultured Hepatocytes. PLoS Comput Biol (2016) 0.83

Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection. BMC Cancer (2015) 0.82

Comparing a knowledge-driven approach to a supervised machine learning approach in large-scale extraction of drug-side effect relationships from free-text biomedical literature. BMC Bioinformatics (2015) 0.82

Integrative analysis of genetic data sets reveals a shared innate immune component in autism spectrum disorder and its co-morbidities. Genome Biol (2016) 0.82

Second act: Drug repurposing gets a boost as academic researchers join the search for novel uses of existing drugs. Proc Natl Acad Sci U S A (2013) 0.82

A genomics-based systems approach towards drug repositioning for rheumatoid arthritis. BMC Genomics (2016) 0.82

Constructing and characterizing a bioactive small molecule and microRNA association network for Alzheimer's disease. J R Soc Interface (2013) 0.82

Genomic medicine and lung diseases. Am J Respir Crit Care Med (2012) 0.82

Integrated analysis of drug-induced gene expression profiles predicts novel hERG inhibitors. PLoS One (2013) 0.82

Advanced systems biology methods in drug discovery and translational biomedicine. Biomed Res Int (2013) 0.82

Drug repositioning by integrating target information through a heterogeneous network model. Bioinformatics (2014) 0.82

Prediction of cancer drugs by chemical-chemical interactions. PLoS One (2014) 0.81

Translational Bioinformatics Approaches to Drug Development. Adv Wound Care (New Rochelle) (2013) 0.81

Unraveling human protein interaction networks underlying co-occurrences of diseases and pathological conditions. J Transl Med (2014) 0.81

A network perspective on unraveling the role of TRP channels in biology and disease. Pflugers Arch (2013) 0.81

Global cancer statistics. CA Cancer J Clin (2011) 185.92

Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88

Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science (1995) 88.48

Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res (2002) 76.95

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99

The price of innovation: new estimates of drug development costs. J Health Econ (2003) 23.43

Using oligonucleotide probe arrays to access genetic diversity. Biotechniques (1995) 12.18

Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics (2006) 10.83

Predicting new molecular targets for known drugs. Nature (2009) 9.71

Drug target identification using side-effect similarity. Science (2008) 9.24

Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov (2004) 7.57

New uses for old drugs. Nature (2007) 5.86

Creation and implications of a phenome-genome network. Nat Biotechnol (2006) 5.79

Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Methods Enzymol (2006) 4.30

Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16

Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol (2005) 3.66

Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55

A network view of disease and compound screening. Nat Rev Drug Discov (2009) 2.90

Finding disease-related genomic experiments within an international repository: first steps in translational bioinformatics. AMIA Annu Symp Proc (2006) 2.88

Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput Biol (2009) 2.84

Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One (2008) 2.66

AILUN: reannotating gene expression data automatically. Nat Methods (2007) 2.47

Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes. BMC Bioinformatics (2005) 2.36

Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput Biol (2009) 2.35

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol (2009) 2.06

Disease signatures are robust across tissues and experiments. Mol Syst Biol (2009) 1.93

Multi-tissue coexpression networks reveal unexpected subnetworks associated with disease. Genome Biol (2009) 1.77

Gene expression signature of estrogen receptor alpha status in breast cancer. BMC Genomics (2005) 1.75

Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69

Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol (2007) 1.63

Successful tumour immunotherapy with cimetidine in mice. Lancet (1981) 1.62

Enabling integrative genomic analysis of high-impact human diseases through text mining. Pac Symp Biocomput (2008) 1.61

Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer (2004) 1.61

Cimetidine reduction of tumour formation in mice. Lancet (1981) 1.48

Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol (2008) 1.45

Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res (2010) 1.37

Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression. Cancer Res (2000) 1.33

Review article: appropriate use of corticosteroids in Crohn's disease. Aliment Pharmacol Ther (2007) 1.21

Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin Cancer Res (2007) 1.20

Data-driven methods to discover molecular determinants of serious adverse drug events. Clin Pharmacol Ther (2009) 1.17

Comparative analysis of gene expression profiles between the normal human cartilage and the one with endemic osteoarthritis. Osteoarthritis Cartilage (2008) 1.17

ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol (2008) 1.15

Inferring novel disease indications for known drugs by semantically linking drug action and disease mechanism relationships. BMC Bioinformatics (2009) 1.12

Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells. Oncogene (2006) 1.10

Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors. IDrugs (2007) 1.09

Old drugs--new uses. Br J Clin Pharmacol (2007) 1.03

Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol Ther (2007) 1.03

Integrative genomics and drug development. Pharmacogenomics (2009) 1.01

POLR2F, ATP6V0A1 and PRNP expression in colorectal cancer: new molecules with prognostic significance? Anticancer Res (2008) 1.01

Predicting drug response based on gene expression. Crit Rev Oncol Hematol (2004) 0.97

Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines. Int J Oncol (2007) 0.96

Cimetidine: an immunomodulator. DICP (1990) 0.94

Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro. Cancer Lett (2008) 0.93

Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells. Int J Cancer (2008) 0.92

Tumour growth inhibition of human pancreatic cancer xenografts in SCID mice by cimetidine. Inflamm Res (2004) 0.91

Cimetidine inhibits angiogenesis and suppresses tumor growth. Biomed Pharmacother (2005) 0.89

Molecular gene expression signature patterns for gastric cancer diagnosis. Comput Biol Chem (2007) 0.88

Anti-tumor effects of cimetidine on hepatocellular carcinomas in diethylnitrosamine-treated rats. Oncol Rep (2008) 0.87

Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor-Trichostatin A through Sp1 binding site. Glia (2009) 0.87

Histone deacetylase inhibitors promote neurosteroid-mediated cell differentiation and enhance serotonin-stimulated brain-derived neurotrophic factor gene expression in rat C6 glioma cells. J Neurosci Res (2009) 0.86

Differential effects of chronic treatment with estrogen receptor ligands on regulation of nitric oxide synthase in porcine aortic endothelial cells. J Cardiovasc Pharmacol (2006) 0.86

Cimetidine inhibits salivary gland tumor cell adhesion to neural cells and induces apoptosis by blocking NCAM expression. BMC Cancer (2008) 0.84

Safety issues relating to long-term treatment with histamine H2-receptor antagonists. Aliment Pharmacol Ther (1993) 0.84

[Effects of cimetidine on the biological behaviors of human gastric cancer cells]. Zhonghua Yi Xue Za Zhi (2006) 0.83

Cimetidine in colorectal cancer--are the effects immunological or adhesion-mediated? Br J Cancer (2002) 0.83

Verapamil inhibits in-vitro leucotriene B4 release by rectal mucosa in active ulcerative colitis. Aliment Pharmacol Ther (1992) 0.83

Verapamil alters eicosanoid synthesis and accelerates healing during experimental colitis in rats. Gastroenterology (1992) 0.83

Cimetidine protection against lethal tumor challenge in mice. Surgery (1981) 0.82

MicroRNA expression profiles classify human cancers. Nature (2005) 69.12

Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature (2010) 23.55

Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A (2003) 17.10

Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell (2012) 12.32

Clinical assessment incorporating a personal genome. Lancet (2010) 10.18

Performance comparison of exome DNA sequencing technologies. Nat Biotechnol (2011) 7.11

Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics (2002) 7.07

Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput Biol (2012) 6.38

Ontology-driven indexing of public datasets for translational bioinformatics. BMC Bioinformatics (2009) 6.31

Performance comparison of whole-genome sequencing platforms. Nat Biotechnol (2011) 5.79

Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med (2011) 5.30

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28

Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer (2008) 5.19

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07

Cell type-specific gene expression differences in complex tissues. Nat Methods (2010) 4.75

An Environment-Wide Association Study (EWAS) on type 2 diabetes mellitus. PLoS One (2010) 4.42

Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell (2011) 3.88

FoxO3 regulates neural stem cell homeostasis. Cell Stem Cell (2009) 3.54

pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. Genes Dev (2007) 3.31

Expression-based genome-wide association study links the receptor CD44 in adipose tissue with type 2 diabetes. Proc Natl Acad Sci U S A (2012) 3.27

Network-based elucidation of human disease similarities reveals common functional modules enriched for pluripotent drug targets. PLoS Comput Biol (2010) 3.23

Phased whole-genome genetic risk in a family quartet using a major allele reference sequence. PLoS Genet (2011) 3.20

Bardet-Biedl syndrome type 4 (BBS4)-null mice implicate Bbs4 in flagella formation but not global cilia assembly. Proc Natl Acad Sci U S A (2004) 3.01

Challenges in the clinical application of whole-genome sequencing. Lancet (2010) 2.92

Comparison of concept recognizers for building the Open Biomedical Annotator. BMC Bioinformatics (2009) 2.83

Systematic survey reveals general applicability of "guilt-by-association" within gene coexpression networks. BMC Bioinformatics (2005) 2.83

Prediction of preadipocyte differentiation by gene expression reveals role of insulin receptor substrates and necdin. Nat Cell Biol (2005) 2.68

Hematopoietic stem cell quiescence is maintained by compound contributions of the retinoblastoma gene family. Cell Stem Cell (2008) 2.67

Characterization of the cell of origin for small cell lung cancer. Cell Cycle (2011) 2.62

Computerized recruiting for clinical trials in real time. Ann Emerg Med (2003) 2.59

PDGF signalling controls age-dependent proliferation in pancreatic β-cells. Nature (2011) 2.53

Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform (2011) 2.52

Quantifying the relationship between co-expression, co-regulation and gene function. BMC Bioinformatics (2004) 2.51

Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes. Kidney Int (2011) 2.50

AILUN: reannotating gene expression data automatically. Nat Methods (2007) 2.47

A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov (2013) 2.46

MicroRNA profiling of human-induced pluripotent stem cells. Stem Cells Dev (2009) 2.44

Systematic evaluation of environmental factors: persistent pollutants and nutrients correlated with serum lipid levels. Int J Epidemiol (2012) 2.42

Translational bioinformatics: linking knowledge across biological and clinical realms. J Am Med Inform Assoc (2011) 2.36

Dynamic microRNA expression programs during cardiac differentiation of human embryonic stem cells: role for miR-499. Circ Cardiovasc Genet (2010) 2.24

Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci U S A (2002) 2.24

Reproducibility of gene expression across generations of Affymetrix microarrays. BMC Bioinformatics (2003) 2.20

A nutrient-wide association study on blood pressure. Circulation (2012) 2.19

Cell type-specific effects of Rb deletion in the murine retina. Genes Dev (2004) 2.18

Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers. Genes Dev (2004) 2.16

Non-synonymous and synonymous coding SNPs show similar likelihood and effect size of human disease association. PLoS One (2010) 2.10

Leveraging models of cell regulation and GWAS data in integrative network-based association studies. Nat Genet (2012) 2.02

A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med (2011) 1.97

Autoimmune disease classification by inverse association with SNP alleles. PLoS Genet (2009) 1.96

Disease signatures are robust across tissues and experiments. Mol Syst Biol (2009) 1.93

Transient inactivation of Rb and ARF yields regenerative cells from postmitotic mammalian muscle. Cell Stem Cell (2010) 1.89

Genome-scale expression profiling of Hutchinson-Gilford progeria syndrome reveals widespread transcriptional misregulation leading to mesodermal/mesenchymal defects and accelerated atherosclerosis. Aging Cell (2004) 1.87

HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A (2010) 1.86

The related retinoblastoma (pRb) and p130 proteins cooperate to regulate homeostasis in the intestinal epithelium. J Biol Chem (2005) 1.85

Novel roles for A-type lamins in telomere biology and the DNA damage response pathway. EMBO J (2009) 1.83

Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res (2010) 1.81

In silico research in the era of cloud computing. Nat Biotechnol (2010) 1.81

A dual role for A-type lamins in DNA double-strand break repair. Cell Cycle (2011) 1.80

Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res (2007) 1.80

Population genetic inference from personal genome data: impact of ancestry and admixture on human genomic variation. Am J Hum Genet (2012) 1.75

Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med (2011) 1.74

Methylation of the retinoblastoma tumor suppressor by SMYD2. J Biol Chem (2010) 1.73

Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care (2013) 1.70

Protein microarrays identify antibodies to protein kinase Czeta that are associated with a greater risk of allograft loss in pediatric renal transplant recipients. Kidney Int (2009) 1.68

The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol (2015) 1.68

Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell (2011) 1.67

An induced Ets repressor complex regulates growth arrest during terminal macrophage differentiation. Cell (2002) 1.63

Translational bioinformatics in the cloud: an affordable alternative. Genome Med (2010) 1.61

Enabling integrative genomic analysis of high-impact human diseases through text mining. Pac Symp Biocomput (2008) 1.61

FitSNPs: highly differentially expressed genes are more likely to have variants associated with disease. Genome Biol (2008) 1.58

Identification of complex metabolic states in critically injured patients using bioinformatic cluster analysis. Crit Care (2010) 1.55

Predicting environmental chemical factors associated with disease-related gene expression data. BMC Med Genomics (2010) 1.55

Type 2 diabetes risk alleles demonstrate extreme directional differentiation among human populations, compared to other diseases. PLoS Genet (2012) 1.55

ImmPort: disseminating data to the public for the future of immunology. Immunol Res (2014) 1.48

Systematic identification of interaction effects between genome- and environment-wide associations in type 2 diabetes mellitus. Hum Genet (2013) 1.48

Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome" measures. Proc Natl Acad Sci U S A (2009) 1.47

A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation. J Exp Med (2013) 1.47

C/EBPbeta cooperates with RB:E2F to implement Ras(V12)-induced cellular senescence. EMBO J (2005) 1.44

Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo. Mol Cell Biol (2003) 1.43

Phylomedicine: an evolutionary telescope to explore and diagnose the universe of disease mutations. Trends Genet (2011) 1.38

Dynamism in gene expression across multiple studies. Physiol Genomics (2009) 1.36

The "etiome": identification and clustering of human disease etiological factors. BMC Bioinformatics (2009) 1.35

Evaluation and integration of 49 genome-wide experiments and the prediction of previously unknown obesity-related genes. Bioinformatics (2007) 1.34